Fig. 3
From: The Kv4 potassium channel modulator NS5806 attenuates cardiac hypertrophy in vivo and in vitro
Effects of NS5806 on surface ECG parameters and susceptibility to ventricular arrhythmia. (A) Representative surface ECG traces (lead II); (B) Summary data for QT intervals; n = 6 for each group; (C) Summary data for mortality from 4 to 8 weeks after TAC and the statistical analysis was performed with Fisher's exact test; (D) Representative ECG traces of Langendorff hearts perfused with epinephrine; (E) Summary data for PVCs. PVCs were recorded for the first 5 min following the initial PVC, and the data were analyzed as PVCs/min. n = 5 for each group; (F) The number of animals with or without VT/VF after epinephrine challenge and the statistical analysis was performed with Fisher's exact test. *P < 0.05, ** P < 0.01 versus the Sham + Vehicle group. #P < 0.05, ##P < 0.01 versus TAC + Vehicle.
